Stay up-to-date with the latest research and clinical updates on bladder cancer from the 2025 ASCO GU Symposium.
Preliminary results of the study showed promising efficacy and safety with neoadjuvant treatment with DV plus toripalimab.
EV with erdafitinib is a feasible combination with the ability to provide promising antitumor activity in mUC.
Dr. Kitamura shares the differences observed between the JAVEMACS and JAVELIN Bladder 100 patient cohorts.
Dr. Hassanzadeh elaborates on the benefits of MDT for patients with progressive or de novo disease.
Neoadjuvant Pembrolizumab and aMVAC for Non-Urothelial MIBC: Does This Combination Improve Outcomes?
Drs. Grivas, Khaki, and Raychaudhuri discuss a phase II trial evaluating pembrolizumab plus aMVAC for non-UC MIBC. 
Dr. Nizam touched on her study of real-world safety of first-line therapies for locally advanced or metastatic UC in the US.
Dr. Jain spoke to the rationale for combining erdafitinib with EV in mUC patients with FGFR3/2 genetic alterations.
Dr. Kim discusses systemic therapy and surgical consolidation in node-positive upper tract urothelial carcinoma treatment.
The ABLE-22 trial evaluates nadofaragene firadenovec alone and in combination for BCG-unresponsive NMIBC.
Neoadjuvant durvalumab plus chemotherapy shows promising pathologic response rates, favorable safety profile in UTUC.
Four experts weigh in on their survey-based study of sequencing after 1L EV/pembro in the evolving landscape of la/mUC.
Drs. Ghatalia and Nizam break down in detail the RETAIN-2 study, a phase 2 trial of risk enabled therapy for MIBC.
EV+P continues to show superior efficacy and durable responses in previously untreated locally advanced or metastatic UC.
Dr. Galsky highlights the latest findings on the impact of pCR on long-term outcomes in the NIAGARA trial.
Dr. Galsky provides comment on the additional efficacy outcomes in patients with MIBC from the CheckMate 274 study.
Dr. Daneshmand provides overviews and updates from three clinical trials involving cretostimogene for high-risk NMIBC.
The interim analysis of the RETAIN-2 trial demonstrated a 46% pT0 rate among those undergoing cystectomy.
New research evaluated the efficacy and safety of durvalumab with intravesical gem/doce in a cohort from ADAPT-BLADDER.
Nivolumab demonstrated sustained DFS benefits across all patients with MIBC and in prior NAC subgroups.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on CheckMate 274, NIAGRA, and more.
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.